Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer.
Alejandro Avilés-SalasDiana Flores-EstradaLuis Lara-MejiaRodrigo CatalánGraciela Cruz-RicoMario Orozco-MoralesDavid HerediaLaura Bolaño-GuerraPamela Denisse Soberanis-PiñaEdgar Varela-SantoyoAndrés F CardonaArrieta OscarPublished in: Thoracic cancer (2022)
Clinicopathological factors were associated with an increased PD-L1 positivity rate. These differences were significant in the PD-L1 high group and associated with the academic setting, the SPS263 clone, time of archival tumor tissue <12 months, and a more recent period in the PD-L1 analysis.